TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05362799
Drug: Letrozol (Femara, Novartis) combined with Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt)
Normalized name: Letrozole
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
Study: NCT05362799
Drug: highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland)
Normalized name: RAYON,PURIFIED
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry.
Study: NCT05362799
Drug: highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) combined with metformin
Normalized name: RAYON,PURIFIED
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
Study: NCT06389682
Drug: 68Ga-NYM005 injection
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: he radiation dose is about 2-7 mCi for a single patient.Using a syringe to withdraw 68Ga-NYM005 injection, the dose will be administered via an intravenous injection and the injection time will be about 45-60 seconds.
Study: NCT05883748
Drug: DISC-1459
Normalized name: xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DISC-1459 dose level 1
Study: NCT05883748
Drug: DISC-1459
Normalized name: xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DISC-1459 dose level 2
Study: NCT06538012
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.
Study: NCT06538012
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
Study: NCT06538012
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT06455280
Drug: Siplizumab
Normalized name: Siplizumab
DrugBank: Siplizumab (DB06371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siplizumab is an anti-CD2 monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD.
Study: NCT06274047
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by PO
Study: NCT06496100
Drug: Triticum Aestivum
Normalized name: Triticum aestivum seed
DrugBank: Triticum aestivum pollen (DB10498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.
Study: NCT05385523
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 8mg dexamethasone in 2 mL.
Study: NCT05385523
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine+ 2 mL normal saline.
Study: NCT05522556
Drug: Ritlecitinib
Normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT04989517
Drug: AT193
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical
Study: NCT05504083
Drug: D-0120
Normalized name: D
DrugBank: Rosomidnar (DB17154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group. Part B: Subjects will be assigned to D-0120 group 3.
Study: NCT05504083
Drug: Benzbromarone
Normalized name: benzbromarone
DrugBank: Benzbromarone (DB12319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
Study: NCT05708742
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The ESP block group underwent US-guided ESP block at L4 vertebrae level with 20 ml of bupivacaine 0.25%.
Study: NCT05708742
Drug: saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control group underwent the same procedure but had a sham injection (20 ml of saline).
Study: NCT00000726
Drug: Foscarnet sodium
Normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06606847
Drug: Oleclumab
Normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleclumab IV (intravenous infusion)
Study: NCT06606847
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab IV (intravenous infusion)
Study: NCT05169957
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab administered IV over 85-100 minutes at 3 mg/kg (combined with nivolumab administered IV over 30-60 minutes at 1 mg/kg) every 3 weeks for a total of 4 doses or until progression or unacceptable toxicity.
Study: NCT05169957
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab administered IV over 30-60 minutes at 1 mg/kg (combined with ipilimumab administered IV over 85-100 minutes at 3 mg/kg) every 3 weeks for a total of 4 doses of the combination therapy or until progression or unacceptable toxicity. Subjects may receive maintenance dosing of nivolumab alone administered IV over 30-60 minutes at 240 mg every 2 weeks or 480 mg every 4 weeks for a maximum of 52 weeks or until progression or unacceptable toxicity.
Study: NCT00002431
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05426681
Drug: GlyBURIDE Oral Tablet
Normalized name: glyburide Oral Tablet
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of spinal cord injury. The dosing regimen involves an initial dose of 1.25mg followed by 11 consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2, and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.~Intervention: Drug: Glyburide
Study: NCT04557384
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC
Study: NCT04739215
Drug: Dapagliflozin 10 MG [Farxiga]
Normalized name: dapagliflozin 10 MG [Farxiga]
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg / day oral
Study: NCT05169944
Drug: Magrolimab
Normalized name: Magrolimab
DrugBank: Magrolimab (DB16225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-cancer therapeutic agent targeting the CD47-signal receptor protein-alpha (SIRP-alpha) axis
Study: NCT06637384
Drug: Hyaluronic Acid (HA)
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gengigel Gingival Gel 20ml, Ricerfarma, Milan, Italy
Study: NCT06637007
Drug: Chidamide Tablets combined with AK112
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chidamide Tablets 30mg/day, po.Bid; AK112（10mg/kg or 20mg/kg）, ivgtt, Q3W.
Study: NCT06643780
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly
Study: NCT06643130
Drug: C2402
Normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For 8 weeks(PO, QD)
Study: NCT05804084
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide tablet (encapsulated)
Study: NCT05383898
Drug: D-1553
Normalized name: D
DrugBank: Rosomidnar (DB17154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
Study: NCT06286098
Drug: Alpha lipoic acid
Normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: THIOTACID 600 MG ORIGINAL ® Tablets manufactured by EVA PHARMA
Study: NCT05168566
Drug: Sutetinib Maleate Capsule
Normalized name: chlorpheniramine maleate Oral Capsule
DrugBank: Sutetinib (DB18841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug to be taken orally with or without food (with food preferred) for up to13 cycles
Study: NCT05313958
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg/㎡/day d1-5 in 2 hours, before the use of Cytarabine
Study: NCT05313958
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5ug/kg/day d0-5,if Peripheral blood leukocytes\<20,000/ul
Study: NCT05313958
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2g/㎡/day d1-5 in 4 hours, after the use of Cladribine
Study: NCT05313958
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
Study: NCT05313958
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
Study: NCT05313958
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg/m2/day was taken orally until molecular biology remission for 2 years
Study: NCT05594589
Drug: Lemborexant
Normalized name: Lemborexant
DrugBank: Lemborexant (DB11951)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lemborexant oral tablet.
Study: NCT06475495
Drug: Rituximab (active comparator)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti CD20 monoclonal antibody
Study: NCT05340205
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 1 gm tranexamic acid diluted in 20 ml of Glucose 5% 15 minutes prior to skin incision and a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following delivery of the baby.
Study: NCT05340205
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 400 microgram misoprostol which will be inserted inside the uterus near the cornu after delivery of the placenta and a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h).~.
Study: NCT05340205
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive an IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby.
Study: NCT06304896
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol 6.25 mg oral tablets. Prescribed: Twice daily PO with 200 mL of water.
Study: NCT06304896
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril 2.5 mg oral capsules. Prescribed: Once daily PO with 200 mL of water.
Study: NCT06304896
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.6 mg oral tablets/capsules. Prescribed: Once daily PO with 200 mL of water.
Study: NCT06446323
Drug: 0.2 ml dose of sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both interventions aim to provide pain relief to neonates following minor procedures by administering sucrose solution orally. The study evaluates the efficacy of each dose (0.2 ml vs. 0.5 ml) in reducing post-procedural pain intensity, as measured by the Premature Infant Pain Profile (PIPP). Additionally, any adverse events associated with the administration of sucrose solution are documented and analyzed as part of the study.
Study: NCT05904379
Drug: AK112
Normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive AK112 intravenously.
Study: NCT05904379
Drug: AK104
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects receive AK104 intravenously.
Study: NCT05904379
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects receive carboplatin intravenously.
Study: NCT05904379
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects receive paclitaxel intravenously.
Study: NCT05904379
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects receive pemetrexed intravenously.
Study: NCT05904379
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects receive docetaxel intravenously.
Study: NCT05156203
Drug: T-1301 Capsules
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-1301 Capsules, 10 and 50 mg, are opaque hard gelatin capsules for oral administration.
Study: NCT05540184
Drug: Trimetazidine 35 mg
Normalized name: trimetazidine 35 MG
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 35mg twice daily will be given to patients before the procedure and 24 hours after the procedure
Study: NCT05540184
Drug: Allopurinol 300 MG
Normalized name: allopurinol 300 MG
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: allopurinol 300 mg once daily 5 hours before the procedure and next day of the procedure
Study: NCT05745883
Drug: DISC-0974
Normalized name: xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DISC-0974 is administered subcutaneously
Study: NCT06054815
Drug: DA-1241
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of Administration: Oral, with subjects in a fasting state
Study: NCT06054815
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Route of Administration: Oral, with subjects in a fasting state
Study: NCT06054815
Drug: Sitagliptin Placebo
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Route of Administration: Oral, with subjects in a fasting state
Study: NCT05377216
Drug: Stellate Ganglion Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Left sided percutaneous stellate ganglion block
Study: NCT04743063
Drug: sacubitril/valsartan
Normalized name: SACUBITRIL/VALSARTAN
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initiation of sacubitril/valsartan, identified using prescription fill in pharmacy claims
Study: NCT04743063
Drug: Angiotensin II Receptor Blockers
Normalized name: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Initiation of ARBs, identified using prescription fill in pharmacy claims
Study: NCT06308926
Drug: MRG-001 (Low-dose)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MRG-001 is subcutaneously administered.
Study: NCT06308926
Drug: MRG-001 (High-dose)
Normalized name: MRG-003
DrugBank: MRG-003 (DB17407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRG-001 is subcutaneously administered.
Study: NCT05486065
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
Study: NCT06695572
Drug: CKD-383
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT06690697
Drug: JS004
Normalized name: Immunoglobulin g4, anti-(human b and t lymphocyte attenuator (btla)) (human-mus musculus monoclonal js004 .gamma.4-chain), disulfide with human-mus musculus monoclonal js004 .kappa.-chain, dimer
DrugBank: Tifcemalimab (DB18914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg, ivdrip, D1, Q3W, each 21 days as a treatment cycle
Study: NCT06690697
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg, ivdrip, D1, Q3W, each 21 days as a treatment cycle
Study: NCT06690697
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg, po, bid, each 21 days as a treatment cycle
Study: NCT06690697
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 g, po, bid, each 21 days as a treatment cycle
Study: NCT05726370
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immunoglobulin G4 monoclonal antibody, via IV infusion
Study: NCT05726370
Drug: CISPLATIN
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Platinum agent, via IV infusion
Study: NCT05726370
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Platinum agent, via IV infusion
Study: NCT05726370
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antineoplastic agent, via IV infusion.
Study: NCT05428670
Drug: Zanubrutinib+Rituximab+Lenalidomide
Normalized name: Zanubrutinib
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zanubrutinib is a bruton' s tyrosine kinase inhibitor independently developed in China.
Study: NCT05950997
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg capsules administered by mouth once daily (28-day cycles)
Study: NCT05950997
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg administered intravenously on Day 1 and 900 mg administered intravenously on Day 2, 1000 mg administered intravenously on Day 8 and 15 of cycle 2 and 1000 mg on Day 1 of subsequent cycles for a total of 6 cycles (28-day cycles)
Study: NCT06570031
Drug: ONO-4578
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06570031
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06570031
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06570031
Drug: abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06570668
Drug: CDD-2101
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will receive 4 sachets of CDD-2101 and/or placebo at a time based on the computer-generated randomization. An unblinded pharmacist will mix the assigned dose of CDD-2101 and/or placebo with 400 mL of water at 70-80°C, cool it to a comfortable temperature and keep it at room temperature for not longer than 1 h. A blinded study nurse or investigator will dispense the suspension to the assigned subject. The subject will drink it under supervision within 15 minutes.
Study: NCT06124495
Drug: Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet (Test or reference)
Study: NCT05120297
Drug: AK101
Normalized name: Azelastine hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive AK101 subcutaneous injection at week 0 and week 4, and will follow up to week 16.